RxDoctor Payments Data

Imran Ismail, DO

Interventional Cardiology · Zephyrhills, FLNPI 1962650028

Payments from drug & device makers

$9,400in general payments, 2019–2025

Across 390 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acist Medical Systems, Inc.$1K
  • Cardiovascular Systems Inc.$934
  • Abbott$572
  • Boston Scientific$558
  • Johnson & Johnson$526
  • Novartis$523
  • plus $5K from 38 others

What the payments were for

  • Travel & lodging$4555%
  • Food & beverage$8,79194%
  • Education$1542%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,400 in reported general payments places this provider in the 45th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$399,622
Medicare patients
1,049
Services billed
3,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$286,788
XareltoRivaroxaban130$154,038
EntrestoSacubitril/Valsartan92$122,131
BrilintaTicagrelor77$52,538
Repatha SyringeEvolocumab39$29,635
JardianceEmpagliflozin12$11,690
Ranolazine ErRanolazine43$4,628
Dabigatran EtexilateDabigatran Etexilate Mesylate11$3,747
Nitroglycerin143$3,470
Metoprolol Succinate313$3,295
Dofetilide20$2,325
ClopidogrelClopidogrel Bisulfate199$1,853
Losartan Potassium175$1,742
Flecainide Acetate30$1,734
Midodrine Hcl26$1,700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$364$286,788257 claims
Johnson & JohnsonXarelto$526$154,038130 claims
NovartisEntresto$523$122,13192 claims
AstraZenecaBrilinta$465$52,53877 claims
Boehringer IngelheimJardiance$504$11,69012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Zephyrhills

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →